Presented data support the ongoing clinical assessment of MT-302, the world's first in vivo mRNA CAR drug development candidate

提供的数据支持正在进行的MT-302临床评估，MT-302是世界上第一个体内mRNA CAR药物开发候选药物

Additional updates highlight Myeloid's pioneering work, including a set of novel mRNA CAR constructs for in vivo programming of additional immune cell subsets, including NK and T cells

其他更新突出了骨髓的开创性工作，包括一组新的mRNA CAR构建体，用于体内编程其他免疫细胞亚群，包括NK和T细胞

CAMBRIDGE, Mass., April 4, 2024 /PRNewswire/ -- Myeloid Therapeutics, Inc. ('Myeloid'), a clinical stage biotechnology company advancing RNA immunotherapies to conquer cancer, announced that it will provide a preclinical update for MT-302, its novel TROP2-targeting RNA CAR at the 2024 American Association for Cancer Research (AACR) Annual Meeting.

马萨诸塞州剑桥，2024年4月4日/PRNewswire/--Myeloid Therapeutics，Inc.（“Myeloid”）是一家临床阶段生物技术公司，致力于推进RNA免疫疗法以征服癌症，宣布将在2024年美国癌症研究协会（AACR）年会上为MT-302（其新型TROP2靶向RNA CAR）提供临床前更新。

MT-302 is currently in a Phase 1 study to assess the therapy's safety and activity in patients with advanced or metastatic epithelial tumors. This advancing study represents the first human trial of any in vivo chimeric antigen receptor (CAR) therapy. Myeloid will also share information on its portfolio of immune cell programming CARs..

MT-302目前正在进行1期研究，以评估该疗法在晚期或转移性上皮肿瘤患者中的安全性和活性。这项先进的研究代表了任何体内嵌合抗原受体（CAR）疗法的首次人体试验。Myeloid还将分享其免疫细胞编程汽车组合的信息。。

'We are thrilled to continue driving this first in vivo mRNA CAR program forward,' said Chief Executive Officer Daniel Getts, Ph.D. 'Myeloid is at the forefront of in vivo immune cell programming. Programming myeloid cells with MT-302 provides significant potential advantages over TROP2-ADCs, in part because MT-302 modified cells can orchestrate a full immune response.' Dr.

首席执行官丹尼尔·盖茨（DanielGetts）博士说：“我们很高兴继续推动这项首次体内mRNA CAR项目的发展。髓样细胞处于体内免疫细胞编程的前沿。用MT-302编程骨髓细胞比TROP2 ADC具有显着的潜在优势，部分原因是MT-302修饰的细胞可以协调完整的免疫反应。”博士。

Getts continued, 'We are also showcasing the basis for an extensive CAR portfolio, extending in vivo programming to a diverse range of immune cell subsets such as NK and T cells. These data underscore the versatility and broad potential of our RNA immunotherapies in revolutionizing cancer treatment.'.

盖茨继续说，“我们还展示了广泛的CAR组合的基础，将体内编程扩展到各种免疫细胞亚群，如NK和T细胞。这些数据强调了我们的RNA免疫疗法在彻底改变癌症治疗方面的多功能性和广泛潜力。”。

The posters presented at AACR underlie Myeloid's strategic vision, that LNP-delivered mRNA CARs can selectively activate targeted immune cells, thus offering cancer patients the potential future opportunity of cell therapy-like outcomes without the need for ex vivo autologous cell handling or allogeneic cell engineering and manufacturing. .

AACR上发布的海报是Myeloid的战略愿景的基础，即LNP递送的mRNA CAR可以选择性激活靶向免疫细胞，从而为癌症患者提供细胞治疗样结果的潜在未来机会，而无需离体自体细胞处理或同种异体细胞工程和制造。

Poster presentation details and abstract highlights include:

海报展示细节和摘要亮点包括：

Date & Time: Monday, April 8, 2024, 9:00 AM – 12:30 PM PT

Date & Time: Monday, April 8, 2024, 9:00 AM – 12:30 PM PT

Title: In vivo Immune Cell Programming Using mRNA-LNP Chimeric Antigen Receptors

标题：使用mRNA-LNP嵌合抗原受体进行体内免疫细胞编程

Location: Poster Section 2

位置：海报第2节

Session Category: Immunology

课程类别：免疫学

Session Title: CAR-NK, NK Engagers, and NK Modulators

课程名称：CAR-NK、NK参与者和NK调制器

Poster Board Number: 4

海报板编号：4

Published Abstract Number: 1321

出版摘要编号：1321

Myeloid has designed novel CARs that achieve expression and function in targeted immune cell populations. These CARs, by activating innate and adaptive immune responses following the in vivo delivery of LNP-formulated mRNA encoded CARs, are capable of eliciting anti-tumor efficacy against a range of multiple target antigens evaluated..

Myeloid设计了新型CAR，可在靶向免疫细胞群中实现表达和功能。这些CAR通过在体内递送LNP配制的mRNA编码的CAR后激活先天性和适应性免疫应答，能够引发针对一系列评估的多种靶抗原的抗肿瘤功效。。

To date, Myeloid has demonstrated CAR activity in human cells, and following systemic mRNA/LNP delivery in mouse and non-human primates.

迄今为止，骨髓已在人类细胞中以及在小鼠和非人灵长类动物中全身性mRNA/LNP递送后证明了CAR活性。

MT302, an in vivo CAR targeting TROP2+ epithelial malignancies (NCT05969041) is undergoing evaluation in a Phase 1 clinical trial, designed to assess the candidate's safety and preliminary efficacy.

MT302是一种靶向TROP2+上皮恶性肿瘤的体内CAR（NCT05969041），正在进行1期临床试验评估，旨在评估候选人的安全性和初步疗效。

Title: In vivo Programming of Natural Killer cells and T cells using mRNA delivered Cytotoxic Chimeric Antigen Receptors

标题：使用mRNA传递的细胞毒性嵌合抗原受体对自然杀伤细胞和T细胞进行体内编程

Location: Poster Section 2

位置：海报第2节

Session Category: Immunology

课程类别：免疫学

Session Title: CAR-NK, NK Engagers, and NK Modulators

课程名称：CAR-NK、NK参与者和NK调制器

Poster Board Number: 2

海报板编号：2

Published Abstract Number: 1319

出版摘要编号：1319

Myeloid's portfolio includes a set of novel CARs designed specifically to program NK and T cells.  These novel CARs are not active in non-immune cells.

Myeloid的产品组合包括一套专门设计用于编程NK和T细胞的新型CAR。这些新型CAR在非免疫细胞中不活跃。

The programed NK cells induce cytotoxicity against antigen-expressing tumor cells and trigger the release of cytokines and chemokines, important factors to a full immune response.

编程的NK细胞诱导针对表达抗原的肿瘤细胞的细胞毒性，并触发细胞因子和趋化因子的释放，这是完全免疫应答的重要因素。

The company further demonstrated that this approach can be used to design receptors for selective expression on the surface of T cells utilizing CD3

该公司进一步证明，这种方法可用于设计利用CD3在T细胞表面选择性表达的受体